VPTDF (VentriPoint Diagnostics) Current Accrued Expense: $0.44 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is VentriPoint Diagnostics Current Accrued Expense?

VentriPoint Diagnostics VPTDF +1.51% Current Accrued Expense is $0.44 Mil as of Dec. 2025. The stock has 4 warning signs investors should review.

VentriPoint Diagnostics's Current Accrued Expense for the quarter that ended in Dec. 2025 was $0.44 Mil.

VentriPoint Diagnostics's quarterly Current Accrued Expense declined from Jun. 2025 ($0.39 Mil) to Sep. 2025 ($0.34 Mil) but then increased from Sep. 2025 ($0.34 Mil) to Dec. 2025 ($0.44 Mil).

VentriPoint Diagnostics's annual Current Accrued Expense declined from Dec. 2023 ($0.22 Mil) to Dec. 2024 ($0.21 Mil) but then increased from Dec. 2024 ($0.21 Mil) to Dec. 2025 ($0.44 Mil).

VentriPoint Diagnostics Current Accrued Expense Related Terms

VentriPoint Diagnostics Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for VentriPoint Diagnostics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VentriPoint Diagnostics Current Accrued Expense Chart

VentriPoint Diagnostics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 0.09 0.22 0.21 0.44

VentriPoint Diagnostics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.21 0.25 0.39 0.34 0.44

VentriPoint Diagnostics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $0.44 Mil mean?
VentriPoint Diagnostics (VPTDF) has a Current Accrued Expense of $0.44 Mil as of Dec. 2025. Current Accrued Expense records the total amount of accrued expenses. View historical data on VentriPoint Diagnostics and its competitors.
Is VentriPoint Diagnostics' Current Accrued Expense too high?
VentriPoint Diagnostics' current Current Accrued Expense is $0.44 Mil.
How does VentriPoint Diagnostics' Current Accrued Expense compare to ABT and SYK?
VentriPoint Diagnostics' Current Accrued Expense of $0.44 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Medical Devices & Instruments company?
A good Current Accrued Expense depends on the Medical Devices & Instruments industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on VentriPoint Diagnostics and its competitors. VentriPoint Diagnostics's current Current Accrued Expense is $0.44 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VentriPoint Diagnostics stock overvalued right now?
VentriPoint Diagnostics (VPTDF) has a current Current Accrued Expense of $0.44 Mil. The current Current Accrued Expense is $0.44 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For VentriPoint Diagnostics (VPTDF), the current Current Accrued Expense is $0.44 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

VentriPoint Diagnostics Business Description

Other Exchanges VPT:Canada
Address 18 Hook Avenue, Unit 101, Toronto, ON, CAN, M6P 1T4
VentriPoint Diagnostics Ltd is a medical device company engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. Its flagship product, the Ventripoint Medical System (VMS+), transforms standard 2D and 3D echocardiography and MRI images into accurate three-dimensional heart models and volumetric measurements, enabling clinicians to assess disease severity, track progression, evaluate treatment response, and guide surgical and pharmacological decisions. Additionally, the company has developed VMS+ 3D Echo and MRI software that can be installed on any personal workstation to create a 3D model of the heart's chamber. Geographically, its products are sold in Canada and internationally.